Aerius

Šalis: Naujoji Zelandija

kalba: anglų

Šaltinis: Medsafe (Medicines Safety Authority)

Veiklioji medžiaga:

Desloratadine 5mg;  

Prieinama:

Bayer New Zealand Limited

INN (Tarptautinis Pavadinimas):

Desloratadine 5 mg

Dozė:

5 mg

Vaisto forma:

Film coated tablet

Sudėtis:

Active: Desloratadine 5mg   Excipient: Calcium hydrogen phosphate dihydrate Carnauba wax Maize starch Opadry blue 32B10817 Opadry Clear YS-1-19025-A Powdered cellulose Purified talc White beeswax

Vienetai pakuotėje:

Blister pack, Aclar/PVC-Al; sample, 2 tablets

Klasė:

Pharmacy only

Recepto tipas:

Pharmacy only

Pagaminta:

MSD International GmbH (Singapore Branch)

Terapinės indikacijos:

The relief of symptoms associated with seasonal and perennial allergic rhinitis, such as sneezing, nasal discharge and itching, congestion/stuffiness, as well as ocular itching, tearing and redness, itching of palate and coughing.

Produkto santrauka:

Package - Contents - Shelf Life: Blister pack, Aclar/PVC-Al; sample - 2 tablets - 24 months from date of manufacture stored at or below 25°C - Blister pack, Aclar/PVC-Al - 10 tablets - 24 months from date of manufacture stored at or below 25°C - Blister pack, Aclar/PVC-Al - 30 tablets - 24 months from date of manufacture stored at or below 25°C

Leidimo data:

1999-11-24

Prekės savybės

 
REF034117-DL-TB-PIPB.2 
DATA SHEET 
AERIUS TABLETS AND SYRUP 

NAME OF MEDICINE 
AERIUS (desloratadine 5 mg) Tablets 
AERIUS (desloratadine 0.5 mg/mL) Syrup 
DESCRIPTION 
AERIUS tablets contain desloratadine 5 mg and the following inactive
ingredients: 

Core: calcium hydrogen phosphate, microcrystalline cellulose, maize
starch and talc 
Coating: Opadry Blue, Opadry Clear, carnauba wax and white beeswax 

AERIUS Syrup contains desloratadine 0.5 mg/mL and the following
inactive ingredients: 

Propylene glycol, sorbitol, anhydrous citric acid, sodium citrate,
disodium edetate, sucrose, bubble 
gum flavour, colour E110, water and sodium benzoate as preservative. 
USES 
_ACTIONS _
Desloratadine is a non-sedating long-acting histamine antagonist with
potent, selective peripheral 
H
1
-receptor antagonist activity. Desloratadine has demonstrated
antiallergic, antihistaminic and 
anti-inflammatory activities. 

_PHARMACODYNAMICS _
After oral administration, desloratadine selectively blocks peripheral
histamine H
1
-receptors 
because the drug is effectively excluded from entry to the central
nervous system. 

In addition to antihistaminic activity, desloratadine has demonstrated
antiallergic and anti-
inflammatory activities from numerous _in vitro (_mainly conducted on
cells of human origin) and _in _
_vi_vo studies. These studies have shown that desloratadine inhibits
the broad cascade of events 
that initiate and propagate allergic inflammation including: 

•  The release of proinflammatory cytokines including IL-4, IL-6,
IL-8, IL-13,  
•  The release of important proinflammatory chemokines such as
RANTES (Regulated upon 
Activation, Normal T-cell Expressed and Secreted),  
•  Superoxide anion production by activated polymorphonuclear
neutrophils,  
•  Eosinophil adhesion and chemotaxis,  
•  The expression of the adhesion molecules such as P-selectin,  
•  IgE-dependent release of histamine, prostaglandin (PGD2), and
leukotriene (LTC4),